The protein Sema3A both restrains bone degradation and stimulates bone building in mice, suggesting a potential therapy for conditions such as osteoporosis. See Article p.69
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 17 May 2023
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Zaidi, M. Nature Med. 13, 791–801 (2007).
Hayashi, M. et al. Nature 485, 69–74 (2012).
Potiron, V. & Roche, J. Sci. STKE 285, pe24 (2005).
He, Z. & Tessier-Lavigne, M. Cell 90, 739–751 (1997).
Mendes-da-Cruz, D. A. et al. Exp. Physiol. http://dx.doi.org/10.1113/expphysiol.2011.061515 (2012).
Chakraborty, G. et al. PLoS ONE 7, e33633 (2012).
Pasterkamp, R. J. et al. Exp. Neurol. 153, 313–327 (1998).
Maione, F. et al. J. Clin. Invest. 119, 3356–3372 (2009).
About this article
Cite this article
Zaidi, M., Iqbal, J. Double protection for weakened bones. Nature 485, 47–48 (2012). https://doi.org/10.1038/485047a
This article is cited by
Signal Transduction and Targeted Therapy (2023)
A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis
Biotechnology Letters (2015)
Nature Reviews Endocrinology (2013)